Sign inJoin waitlistJoin the waitlist

Mario Lacouture

Chief, Division of Dermatology · NYU Grossman Long Island School of Medicine

Credentials: · · · ·

History

Division of Dermatology · NYU Grossman Long Island School of Medicine
Present
Division of Dermatology · NYU Grossman Long Island School of Medicine
Present
Symptom Management Program · NYU Grossman Long Island School of Medicine
Present

Hematology and Medical Oncology
2011–2014
Dermatology
SUNY Downstate Health Sciences University
2007–2011
Doctor of Medicine
2003–2007
Dermatology
University of Chicago Medical Center
2002–2005

Research

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
Journal for ImmunoTherapy of Cancer · 2017 · 1,572 citations
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Review · Annals of Oncology · 2015 · 1,118 citations
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Journal for ImmunoTherapy of Cancer · 2021 · 762 citations

Shenhong Wu
35 papers
AM
Alina Markova
28 papers
Jerry Shapiro
21 papers
KB
Klaus Busam
20 papers
SG
Shari Goldfarb
18 papers
Yevgeniy Balagula
16 papers · 13 as a resident
Kristen Sicco
15 papers
Milan Anadkat
13 papers
Omar Abdel-Wahab
13 papers
Alyx Aigen
12 papers · 4 as a resident
Eli Diamond
12 papers
Veronica Rotemberg
12 papers · 1 as a resident

Grants

Identification of Pathways to Mitigate Immune-Related Adverse Events with Cancer Immunotherapy
National Institute of Arthritis and Musculoskeletal and Skin Diseases · U01
PI · $3.1M · National Jewish Health
2020–2026

Clinical trials

A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients
Principal investigator · Unknown · Phase 2
OnQuality Pharmaceuticals (USA) LLC
2019–2024
Study Determining Safety and Efficacy of Avena Sativa (Oat) Skincare Products for Treating Skin Dryness and Itching in Cancer Patients
Principal investigator · Completed
Johnson & Johnson Consumer Inc. (J&JCI)
2019
Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT
Principal investigator · Completed · Phase 3
Memorial Sloan Kettering Cancer Center
2013–2015
Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Chemotherapy-Induced Alopecia
Principal investigator · Completed · Phase 1
BPGbio
2012–2017